Baumgartner, Joel M.
Riviere, Paul
Lanman, Richard B.
Kelly, Kaitlyn J.
Veerapong, Jula
Lowy, Andrew M.
Kurzrock, Razelle
Funding for this research was provided by:
Joan and Irwin Jacobs Fund philanthropic fund
National Cancer Institute (CA023100)
National Institutes of Health (TL1TR001443)
Guardant Health
Article History
Received: 30 June 2019
First Online: 6 August 2020
Financial support
: Funded in part by the National Cancer Institute (grant P30 CA023100) and the Joan and Irwin Jacobs Fund philanthropic fund. Study also funded in part by the Guardant Health (Guardant Health, Inc., Redwood City, CA). The project described was partially supported by the National Institutes of Health (grant TL1TR001443 of CTSA funding beginning August 13, 2015 and beyond). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH.
: Razelle Kurzrock discloses stock and other equity interests (IDbyDNA, CureMatch, Inc., and Soluventis); consulting or advisory role (Gaido, LOXO, X-Biotech, Actuate Therapeutics, Roche, NeoMed, Soluventis, and Pfizer); speaker’s fee (Roche); research Fundingf [Incyte, Genentech, Merck Serono, Pfizer, Sequenom, Foundation Medicine, Guardant Health, Grifols, Konica Minolta, DeBiopharm, Boerhringer Ingelheim, and OmniSeq (all institutional)]; board member (CureMatch, Inc). Paul Riviere discloses consulting fees from Peptide Logic, LLC. Richard Lanman is an employee of Guardant Health, Inc.